- Capital Cube•20 days ago
Click here to see latest analysisCapitalcube gives OncoMed Pharmaceuticals, Inc. a score of 29.Our analysis is based on comparing OncoMed Pharmaceuticals, Inc. with the following peers – Celgene Corporation, Regeneron Pharmaceuticals, Inc., Acceleron Pharma Inc, Endocyte, Inc., GlaxoSmithKline plc Sponsored ADR, Stemline Therapeutics, Inc., Verastem, Inc., ImmunoCellular Therapeutics, Ltd. and Cerulean Pharma, Inc. (CELG-US, REGN-US, […] (Read more...) The post OncoMed Pharmaceuticals, Inc. – Value Analysis (NASDAQ:OMED) : July 5, 2016 appeared first on CapitalCube.
- Capital Cube•21 days agoOncoMed Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : OMED-US : July 4, 2016
Click here to see latest analysis*Disclaimer : This is as of previous day’s closing price.Technical IndicatorsBelow is a quick look at 5 technical indicators for OncoMed Pharmaceuticals, Inc.. More studies are available on the Technical Chart.IndicatorSignalClosing Price above/below 50 Day Moving AverageBullishClosing Price above/below 200 Day Moving AverageBearish50 Day Moving Average above/below 200 Day Moving […] (Read more...) The post OncoMed Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : OMED-US : July 4, 2016 appeared first on CapitalCube.
OncoMed Pharmaceuticals, Inc.NasdaqGS
After hours: 12.180.00 (0.00%) as of 4:44 PM EDT
|Bid||11.28 x 200|
|52wk Range||8.42 - 23.98|
|Day's Range||12.06 - 12.34|
|Avg Vol (3m)||182,446|
As of 4:00 PM EDT. Market closed.